A Study of BBI503 in Combination With Selected Anti-Cancer Therapeutics in Adult Patients With Advanced Cancer
Status:
Completed
Trial end date:
2019-05-01
Target enrollment:
Participant gender:
Summary
This is an open label, multi-center, Phase 1/2 study of BBI503 administered in combination
with selected anti-cancer therapeutics in adult patients with advanced cancer. The goal of
the study is to determine the safety, tolerability, and RP2D of BBI503 in combination with
each of the selected anti-cancer agents.
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
Boston Biomedical, Inc Sumitomo Dainippon Pharma Oncology, Inc